AMARILLO BIOSCIENCES INC
10QSB, EX-27, 2000-11-13
PHARMACEUTICAL PREPARATIONS
Previous: AMARILLO BIOSCIENCES INC, 10QSB, 2000-11-13
Next: CLARK WORLEY H JR, 4, 2000-11-13



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2000 AND THE CONSOLIDATED
STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000. AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS INCLUDED IN
THIS FORM 10-QSB FOR PERIODS ENDED SEPTEMBER 30, 2000.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         655,445
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                     48,639
<CURRENT-ASSETS>                               749,782
<PP&E>                                         250,507
<DEPRECIATION>                                 154,113
<TOTAL-ASSETS>                                 932,368
<CURRENT-LIABILITIES>                          861,302
<BONDS>                                      2,000,000
                                0
                                          0
<COMMON>                                        78,074
<OTHER-SE>                                 (2,007,008)
<TOTAL-LIABILITY-AND-EQUITY>                   932,368
<SALES>                                              0
<TOTAL-REVENUES>                                48,376
<CGS>                                                0
<TOTAL-COSTS>                                2,015,895
<OTHER-EXPENSES>                               844,403
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              60,140
<INCOME-PRETAX>                            (2,872,062)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,872,062)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,872,062)
<EPS-BASIC>                                      (.37)
<EPS-DILUTED>                                    (.37)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission